Strides Arcolab, Eli Lilly collaborate to expand marketing of cancer medicines

Strides Arcolab, Eli Lilly collaborate to expand marketing of cancer medicinesBangalore-based Strides Arcolab Ltd has join forces with US-based pharmaceuticals firm Eli Lilly & Co to expand the marketing of generic oral as well as injectable cancer medicines in emerging markets.

As a part of the partnership deal, Eli Lilly will in-license a portfolio of branded generic cancer treatment drugs manufactured by Agila Specialties - the specialties arm of Strides Arcolab Ltd.

In other words, Agila will manufacture the cancer treatment drugs and Eli Lilly will register and market them in various geographies across emerging markets, including India.

Agila, whose key domains include oncolytics, biosimilars, penicillins and ophthalmics, operates a total of nine manufacturing facilities in various countries of the world, which includes a steriles manufacturing facility in India.

Commenting on the deal, Strides Group CEO Arun Kumar said, "We are delighted to partner with Eli Lilly to expand its branded generics platform with high-quality oncology products..."

Jacques Tapiero, senior vice president of Eli Lilly, said that the agreement would help Eli Lilly further expand its portfolio and deliver high-quality cancer treatment drugs to patients across emerging markets.

However, the deal will not take effect in the market before the second half of the next year.